Distributor Obligations Under EU MDR Article 14

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Under Article 14 of the MDR, distributors must, before making a device available on the market, verify that it bears the CE marking, is accompanied by the required information and instructions for use, and has been assigned a UDI where applicable, and they must verify that the manufacturer, the authorised representative and the importer have fulfilled their respective obligations. Where a distributor considers a device non-compliant, it must not make it available on the market and must inform the manufacturer and, where applicable, the authorised representative and the importer. Compared with the importer regime in Article 13, the distributor’s verification covers the obligation fulfilment of three upstream parties, which in practice means being able to locate the manufacturer’s EUDAMED registration record and the importer’s identification information. Distributors must also ensure that storage and transport conditions within their sphere of responsibility do not compromise conformity, cooperate with competent authorities on sampling and traceability requests, and — like importers — can be deemed manufacturers under Article 16 where they supply devices under their own name or trademark, relabel, repackage or translate the accompanying information. Building these duties into a batch-level release workflow keeps the evidence coherent.

2. Legal basis

The distributor regime rests on the following provisions and guidance documents.

Regulation / documentProvisionsDatesSource
Regulation (EU) 2017/745Article 14 (distributor obligations); Article 14(2) (verification before making devices available); Article 14(4) (storage and transport)Adopted 2017-04-05; applicable 2021-05-26EUR-Lex
Regulation (EU) 2017/745Article 2(35) (definition of distributor); Article 16 (cases in which relabelling and similar acts make the distributor a manufacturer)Same as aboveEUR-Lex
European Commission factsheet on authorised representatives, importers and distributorsOverview of roles and responsibilitiesCurrenthealth.ec.europa.eu

3. Expert insights

Insight one: the distributor verifies the obligation fulfilment of three parties, which is broader than the importer’s check.

Article 14 requires the distributor to verify that the manufacturer, the authorised representative and the importer have fulfilled their obligations. This goes further than inspecting the physical product. In practical terms it means a distributor should be able to find the manufacturer’s EUDAMED registration record and the importer’s identification information on the device or its accompanying documents. A distributor that only checks the CE marking and the outer carton has performed part of the duty; the traceability logic of the MDR assumes that each economic operator in the chain can name and verify its upstream counterparties. Distributors supplying devices from multiple importers should therefore keep a supplier-level register that records, for each manufacturer, representative and importer, the evidence of registration and identification that was verified before making devices available.

Insight two: distributors do not necessarily deal with competent authorities directly, but the notification duty is hard-edged.

Where a distributor identifies a non-compliant device, or a device suspected of being falsified or presenting a serious risk to health, it must inform the manufacturer and, where applicable, the authorised representative and the importer, and notify the competent authorities. The European Commission factsheet likewise states that importers should notify competent authorities when they suspect a device has been falsified or presents a serious risk to health. The duty to stop supplying and to notify operates as a pair: suspending supply alone, without the notification, does not discharge the obligation, and the procedure should name the recipients and the timelines for both actions.

Insight three: distributors, too, can escalate into manufacturers.

Under Article 16, a distributor that makes devices available under its own name or trademark, relabels them, repackages them or translates the accompanying information is deemed to be a manufacturer. The most common triggers are own-brand labelling arrangements and the localisation of instructions for use into additional languages — the latter is frequently mistaken for a pure translation exercise, when legally it shifts the regulatory role. Commercial teams planning own-brand ranges should involve compliance early, because the Article 10 obligations that follow include the quality management system required by Article 16(3).

Insight four: the storage and transport duty runs parallel to the importer’s, at every tier.

Article 14 requires the distributor, within its sphere of responsibility, to ensure that storage and transport conditions do not compromise conformity, and to cooperate with competent authorities on sampling and traceability requests as required. In a multi-tier distribution network, this obligation applies independently at each tier, so every warehouse and every logistics leg in the chain must be able to demonstrate the conditions it maintained. Distributors should treat condition records as part of their distribution records, alongside lot numbers, quantities and delivery destinations.

4. Practical recommendations

  1. Establish a verification checklist applied before devices are made available, and retain batch-level verification records.
  2. Establish a stop-supply-plus-notify dual-action procedure for non-compliant devices, naming the recipients and timelines for the notifications.
  3. For temperature- and humidity-sensitive products, establish records of storage and transport conditions and a deviation handling procedure.
  4. Assess whether own-brand business and instructions-for-use localisation trigger Article 16.
  5. Maintain distribution records (lot numbers, quantities, delivery destinations) to support traceability and the execution of field safety corrective actions (FSCA).

5. Verification checklist

Confirm each of the following items as part of the distributor’s standing compliance system.

  • □ A verification checklist is established and filed batch by batch before devices are made available
  • □ CE marking, accompanying information and UDI have been verified
  • □ The obligation fulfilment of the manufacturer, the authorised representative and the importer has been verified
  • □ The stop-supply and notification procedure for non-compliant devices is established
  • □ Records of storage and transport conditions are established
  • □ Whether the role change under Article 16 is triggered has been assessed

Regulatory information verified as of 29 October 2026.

GRZAN works with distributors and importers active in the European Union market under the EU MDR, providing EU Authorised Representative (AR) and PRRC services, EUDAMED registration support, verification and traceability workflow design, and fee and budget planning for notified body conformity assessment. Our team helps distributors evidence their Article 14 verification duties, storage and transport conditions and notification procedures, and assesses Article 16 role changes before own-brand or localisation projects start. For practical support with registration, distribution compliance and budget matters under Regulation (EU) 2017/745, contact GRZAN at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail